BRNS: Barinthus Biotherapeutics plc - ADR Company Profile & Statistics

About

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases. The company's product pipeline includes VTP-300, VTP-200, VTP-1000, VTP-850 and VTP-1100. Barinthus Biotherapeutics plc, formerly known as Vaccitech plc, is based in OXFORD, United Kingdom.

Info & Links

CEO

William Enright

Headquarters

UNIT 6-10, ZEUS BUILDING, RUTHERFORD AVENUE
DIDCOT, X0 OX11 0DF, UNITED KINGDOM

Auditor

PricewaterhouseCoopers LLP

Share holders

Employees

105

Barinthus Biotherapeutics plc - ADR Statistics

Valuation Measures

Market Capitalization²

38.74M

Enterprise Value

-73.66M

Enterprise Value/EBITDA(ttm)

1.18

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

Price to Book(mrq)

0.27

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

25.00%

Operating Margin(ttm)

Profit Margin(ttm)

-13.55%

Return on Equity(ttm)

-34.26%

Return on Invested Capital(ttm)

-40.75%

Return on Assets(ttm)

-29.30%

Income Statement

Revenue(ttm)

14.97M

Revenue Per Share(ttm)

0.37

Gross Profit(ttm)

14.97M

EBITDA(ttm)³

-62.17M

Net Income Available to Common(ttm)

-61.07M

Diluted EPS(ttm)

-1.49

Share Statistics

Beta (5Y Monthly)

-0.82

52-Week Change

-56.50%

S&P 500 52-Week Change

12.30%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

40.34M

Dividend Yield

0.00%

Float⁴

37.01M

% Held by Insiders

8.00%

% Held by Institutions

25.20%

Balance Sheet

Total Cash(mrq)

112.40M

Total Cash Per Share(mrq)

2.79

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

8.03%

Quick Ratio(mrq)

8.93%

Book Value Per Share(mrq)

3.23

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.74

Free Cash Flow(ytd)

-29.83M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

BRNS

Barinthus Biotherapeutics plc - ADR

Barinthus Biotherapeutics plc - ADR Profile